Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Oct;66(4):723–727. doi: 10.1038/bjc.1992.346

Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.

L L Thomsen 1, B C Baguley 1, G J Rustin 1, S M O'Reilly 1
PMCID: PMC1977435  PMID: 1419615

Abstract

Plasma samples were collected from 20 patients undergoing phase I clinical trial with flavone-8-acetic acid (FAA; 4.8 g m-2 per dose) in combination with recombinant human interleukin-2 (rhIL-2; 6-18 i.u. m-2 per day) for the treatment of metastatic melanoma. Samples were analysed for nitrate content as an indication of the oxidation of L-arginine to nitric oxide. Pretreatment plasma nitrate levels (53 +/- 4 microM) were significantly above those of healthy volunteers (19 +/- 4 microM). The maximum plasma nitrate concentration obtained after treatment, 190 +/- 29 microM (range 49 to 655 microM), was comparable to that of mice treated with FAA. Most of the increases occurred 3-5 days after initiation of a 5 day infusion of rhIL-2, but three of the increases occurred within 2 days of a 1 h infusion of FAA alone. The maximum plasma nitrate concentrations of the three patients which underwent remission (two complete, one partial) following treatment (368 +/- 143 microM) were significantly higher (P < 0.05) than those of patients with progressive disease. Hypotension was the major dose-limiting side effect, and there was no relationship between the degree of hypotension and the rise in plasma nitrate. The results provide evidence that treatment of patients with FAA and rhIL-2 induce the synthesis of nitric oxide, a physiological mediator and potential cytotoxic agent.

Full text

PDF
723

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balkwill F., Osborne R., Burke F., Naylor S., Talbot D., Durbin H., Tavernier J., Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet. 1987 Nov 28;2(8570):1229–1232. doi: 10.1016/s0140-6736(87)91850-2. [DOI] [PubMed] [Google Scholar]
  2. Blay J. Y., Favrot M. C., Negrier S., Combaret V., Chouaib S., Mercatello A., Kaemmerlen P., Franks C. R., Philip T. Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. Cancer Res. 1990 Apr 15;50(8):2371–2374. [PubMed] [Google Scholar]
  3. Boccoli G., Masciulli R., Ruggeri E. M., Carlini P., Giannella G., Montesoro E., Mastroberardino G., Isacchi G., Testa U., Calabresi F. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment. Cancer Res. 1990 Sep 15;50(18):5795–5800. [PubMed] [Google Scholar]
  4. Ching L. M., McKeage M. J., Joseph W. R., Kestell P., Zwi L. J., Baguley B. C. Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid. Cancer Chemother Pharmacol. 1991;28(6):414–419. doi: 10.1007/BF00685816. [DOI] [PubMed] [Google Scholar]
  5. Clarke J. G., Benjamin N., Larkin S. W., Webb D. J., Davies G. J., Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989 Dec;257(6 Pt 2):H2033–H2035. doi: 10.1152/ajpheart.1989.257.6.H2033. [DOI] [PubMed] [Google Scholar]
  6. Creaven P. J., Brenner D. E., Cowens J. W., Huben R. P., Wolf R. M., Takita H., Arbuck S. G., Razack M. S., Proefrock A. D. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol. 1989;23(3):186–191. doi: 10.1007/BF00267953. [DOI] [PubMed] [Google Scholar]
  7. Engelhardt R., Mackensen A., Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res. 1991 May 15;51(10):2524–2530. [PubMed] [Google Scholar]
  8. Gemlo B. T., Palladino M. A., Jr, Jaffe H. S., Espevik T. P., Rayner A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Oct 15;48(20):5864–5867. [PubMed] [Google Scholar]
  9. Green L. C., Wagner D. A., Glogowski J., Skipper P. L., Wishnok J. S., Tannenbaum S. R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem. 1982 Oct;126(1):131–138. doi: 10.1016/0003-2697(82)90118-x. [DOI] [PubMed] [Google Scholar]
  10. Hibbs J. B., Jr, Westenfelder C., Taintor R., Vavrin Z., Kablitz C., Baranowski R. L., Ward J. H., Menlove R. L., McMurry M. P., Kushner J. P. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest. 1992 Mar;89(3):867–877. doi: 10.1172/JCI115666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaye S. B., Clavel M., Dodion P., Monfardini S., ten Bokkel-Huinink W., Wagener D. T., Gundersen S., Stoter G., Smith J., Renard J. Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Invest New Drugs. 1990;8 (Suppl 1):S95–S99. doi: 10.1007/BF00171993. [DOI] [PubMed] [Google Scholar]
  12. Kilbourn R. G., Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst. 1990 May 2;82(9):772–776. doi: 10.1093/jnci/82.9.772. [DOI] [PubMed] [Google Scholar]
  13. Kilbourn R. G., Gross S. S., Jubran A., Adams J., Griffith O. W., Levi R., Lodato R. F. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A. 1990 May;87(9):3629–3632. doi: 10.1073/pnas.87.9.3629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lancaster J. R., Jr, Hibbs J. B., Jr EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc Natl Acad Sci U S A. 1990 Feb;87(3):1223–1227. doi: 10.1073/pnas.87.3.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leaf C. D., Wishnok J. S., Hurley J. P., Rosenblad W. D., Fox J. G., Tannenbaum S. R. Nitrate biosynthesis in rats, ferrets and humans. Precursor studies with L-arginine. Carcinogenesis. 1990 May;11(5):855–858. doi: 10.1093/carcin/11.5.855. [DOI] [PubMed] [Google Scholar]
  16. Mace K. F., Hornung R. L., Wiltrout R. H., Young H. A. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res. 1990 Mar 15;50(6):1742–1747. [PubMed] [Google Scholar]
  17. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  18. O'Dwyer P. J., Shoemaker D., Zaharko D. S., Grieshaber C., Plowman J., Corbett T., Valeriote F., King S. A., Cradock J., Hoth D. F. Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent. Cancer Chemother Pharmacol. 1987;19(1):6–10. doi: 10.1007/BF00296246. [DOI] [PubMed] [Google Scholar]
  19. Plowman J., Narayanan V. L., Dykes D., Szarvasi E., Briet P., Yoder O. C., Paull K. D. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep. 1986 May;70(5):631–635. [PubMed] [Google Scholar]
  20. Thiemermann C., Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol. 1990 Jul 17;182(3):591–595. doi: 10.1016/0014-2999(90)90062-b. [DOI] [PubMed] [Google Scholar]
  21. Thomsen L. L., Ching L. M., Baguley B. C. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res. 1990 Nov 1;50(21):6966–6970. [PubMed] [Google Scholar]
  22. Thomsen L. L., Ching L. M., Zhuang L., Gavin J. B., Baguley B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res. 1991 Jan 1;51(1):77–81. [PubMed] [Google Scholar]
  23. Urba W. J., Longo D. L., Lombardo F. A., Weiss R. B. Enhancement of natural killer activity in human peripheral blood by flavone acetic acid. J Natl Cancer Inst. 1988 Jun 1;80(7):521–525. doi: 10.1093/jnci/80.7.521. [DOI] [PubMed] [Google Scholar]
  24. Wiltrout R. H., Boyd M. R., Back T. C., Salup R. R., Arthur J. A., Hornung R. L. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol. 1988 May 1;140(9):3261–3265. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES